Literature DB >> 7149491

Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis.

A D Sniderman, C Wolfson, B Teng, F A Franklin, P S Bachorik, P O Kwiterovich.   

Abstract

Researchers disagree on whether plasma triglyceride levels are an independent risk factor for atherosclerotic coronary artery disease. We hypothesized that patients with endogenous hypertriglyceridemia would differ: Some would have normal values of plasma low-density lipoprotein (LDL) B protein; others, despite their normal level of LDL cholesterol, would have increased levels of LDL B protein. We believe the latter patients--those with hyperapobetalipoproteinemia--would be the ones at risk for atherosclerosis. We studied two populations. Group 1, consisting of 162 patients with type IV lipoprotein patterns, was divided into two groups. One subgroup (A), which included 38 patients with elevated plasma LDL B atherosclerotic disease than the other subgroup (B) of 36 patients with normal levels of plasma LDL B protein (10 patients versus two, p less than 0.02). Group 2 consisted of 100 patients who had had myocardial infarction. Eighty-one percent of the 47 hypertriglyceridemic and 70% of the 53 normotriglyceridemic patients had elevated plasma LDL B protein levels (129 mg/dL or greater)--a proportion significantly higher than that in Group 1 (p less than 0.001). Thus, an elevated plasma level of LDL B protein not only identifies subgroups of patients with type IV lipoprotein patterns, but also may be an important marker for atherosclerotic disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7149491     DOI: 10.7326/0003-4819-97-6-833

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  30 in total

Review 1.  Insulin resistance and cardiovascular disease.

Authors:  H N Ginsberg
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 2.  The Gordon Wilson Lecture. Plasma cholesterol: atherogenesis and mortality.

Authors:  W R Fisher
Journal:  Trans Am Clin Climatol Assoc       Date:  1993

Review 3.  Plasma high density lipoproteins. Metabolism and relationship to atherogenesis.

Authors:  A R Tall
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

4.  Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction.

Authors:  P N Durrington; L Hunt; M Ishola; J Kane; W P Stephens
Journal:  Br Heart J       Date:  1986-09

5.  Pedigree and sib-pair linkage analysis suggest the apolipoprotein B gene is not the major gene influencing plasma apolipoprotein B levels.

Authors:  J Coresh; T H Beaty; P O Kwiterovich; S E Antonarakis
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

Review 6.  Guidelines for the detection of high-risk lipoprotein profiles and the treatment of dyslipoproteinemias. Canadian Lipoprotein Conference Ad Hoc Committee on Guidelines for Dyslipoproteinemias.

Authors: 
Journal:  CMAJ       Date:  1990-06-15       Impact factor: 8.262

Review 7.  Normal and pathological lipoprotein metabolism.

Authors:  G R Thompson
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 8.  Apolipoproteins in lipid transport, an impressionist view.

Authors:  D W Erkelens
Journal:  Postgrad Med J       Date:  1989-05       Impact factor: 2.401

Review 9.  Genetic influences on susceptibility to atherosclerosis in the young.

Authors:  P O Kwiterovich
Journal:  Bull N Y Acad Med       Date:  1989-12

10.  Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia.

Authors:  B Teng; G R Thompson; A D Sniderman; T M Forte; R M Krauss; P O Kwiterovich
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.